Inhibitor of the release of mast cell mediators does not improve the psoriatic plaque.
The number of mast cells is increased in psoriatic lesions and this is particularly prominent in their early phase. Mediators released by mast cells may interfere with various aspects of cutaneous inflammation and epidermal proliferation. Therefore, the aim of the present investigation was to find out whether a 4-week treatment period with Tiacrilast, a highly potent inhibitor of mast cell degranulation, might have antipsoriatic potential. A total of 31 patients with plaque-type psoriasis were evaluated after treatment with a 3% Tiacrilast hydrogel and hydrogel alone, in a double-blind, placebo-controlled, within-patient comparative study. No statistically significant improvement of the Tiacrilast-treated plaques compared to the hydrogel-treated sites could be demonstrated. Therefore, the present study does not provide evidence of a potential role of mast cell degranulation in the treatment of psoriasis.
van de Kerkhof
P C
PC
Department of Dermatology, University of Nijmegen, The Netherlands.
Goos
M
M
Christophers
E
E
Baudin
M
M
Dupuy
P
P
D000328:Adult; D015550:Cell Degranulation / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008407:Mast Cells / Q000187:drug effects*; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*
D006634:Histamine H1 Antagonists; D011799:Quinazolines; C040252:tiacrilast